Cefuroxime Axetil I.P. 250 mg.
Cefuroxime Axetil is an orally administered prodrug of cefuroxime — a second-generation cephalosporin antibiotic. Following oral administration, cefuroxime axetil undergoes rapid hydrolysis by intestinal esterases during absorption, releasing the active cefuroxime moiety into systemic circulation. Cefuroxime exerts its bactericidal action by binding to penicillin-binding proteins (PBPs) — specifically PBP1 and PBP2 — on the bacterial cytoplasmic membrane. These enzymes are responsible for the transpeptidation reactions that cross-link peptidoglycan strands in the bacterial cell wall. Inhibition causes structural compromise, osmotic instability, and bacterial lysis.
As a second-generation cephalosporin, cefuroxime retains strong activity against gram-positive organisms while demonstrating significantly enhanced coverage against gram-negative pathogens compared to first-generation agents — including H. influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, E. coli, Klebsiella species, and Proteus mirabilis. Cefuroxime demonstrates stability against many common beta-lactamases, including those produced by H. influenzae — a particularly important feature for ENT and respiratory infections where this organism predominates.
BOLDTIL™ 250 is indicated for mild to moderate bacterial infections caused by cefuroxime-susceptible organisms across ENT, respiratory, urinary, and skin indications.
Upper Respiratory Tract Infections: Acute bacterial sinusitis, acute otitis media, pharyngitis, and tonsillitis — where cefuroxime demonstrates excellent tissue penetration and superior outcomes to amoxycillin against beta-lactamase-producing pathogens.
Lower Respiratory Tract Infections: Community-acquired pneumonia, acute exacerbations of chronic bronchitis, and bronchitis unresponsive to amoxycillin.
Urinary Tract Infections: Uncomplicated cystitis and pyelonephritis, particularly where E. coli or Klebsiella are suspected.
Skin and Soft Tissue Infections: Impetigo, cellulitis, wound infections, and folliculitis caused by S. aureus and Streptococcus pyogenes.
Lyme Disease: Early localised Lyme disease — a specific and guideline-recommended indication for cefuroxime axetil in patients where doxycycline is contraindicated.
Bone and Joint Infections: Step-down oral therapy following parenteral cephalosporin treatment of osteomyelitis and septic arthritis.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
In ENT practice, the most common reason for antibiotic treatment failure in acute otitis media and sinusitis is the presence of beta-lactamase-producing H. influenzae and M. catarrhalis — organisms that readily destroy amoxycillin but remain susceptible to cefuroxime. BOLDTIL™ 250 directly addresses this gap, offering ENT specialists a reliable oral step-up option that covers the pathogens responsible for first-line treatment failures without requiring parenteral therapy.
The prodrug design of cefuroxime axetil is a clinically important feature: food significantly enhances its absorption, meaning the doctor's instruction to take the tablet after meals is not merely a tolerability suggestion but a pharmacokinetic necessity. Franchise partners can leverage this as a patient counselling point that differentiates BOLDTIL™ 250 from generic competitors and builds prescriber confidence in the Seclis Labs brand.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.